With his expertise, he evaluates your medical history, weight loss goals, and overall health to determine which medication will provide the best results for you
A meta-analysis of 5 trials (n=20,387) estimated that SGLT2i use in people with advanced diabetic kidney disease reduced the risk of kidney failure by 31% (HR 0.69, 95% CI 0.57 to 0.83) [58] Note that this is over and above the effect of both BP control and use of RAASis
Semaglutide GLP-1 can help patients achieve considerable weight loss and avoid many of the adverse health outcomes associated with obesity
Footnotes CONFLICTS OF INTEREST Hideaki Jinnouchi has received honoraria from Novo Nordisk, Sanofi, Eli Lilly, Mitsubishi Tanabe Pharma, and Otsuka Pharmaceutical
Oligomerization of a glucagon-like peptide-1 analog: bridging experiment and simulations
thus, GLP-1RAs are favorable candidates for repurposing for the treatment of neurodegenerative diseases